PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform. The company develops anticancer paradigms, including fimaCHEM, a chemotherapeutics for treatment of cancer; fimaVACC, a T-cell induction technology for therapeutic vaccination, which is in Phase I clinical study; and fimaNAc, a nucleic acid therapeutics delivery technology, which is in pre-clinical study. It also offers Amphinex, a photosensitiser fimaporfin. The company has collaborative research programs with Bavarian Nordic, BioNTech, Phio Pharmaceuticals, DCprime, eTheRNA immunotherapies, IMV, and Aposense. PCI Biotech Holding ASA is based in Oslo, Norway.
प्रकार | 5 मिनट | 15 मिनट | प्रति घंटा | दैनिक | मासिक |
---|---|---|---|---|---|
मूविंग एवरेज | खरीदें | तटस्थ | बेचना | बेचना | मजबूत विक्रय |
तकनीकी संकेतक | खरीदें | खरीदें | मजबूत खरीद | मजबूत खरीद | मजबूत विक्रय |
सारांश | खरीदें | तटस्थ | तटस्थ | तटस्थ | मजबूत विक्रय |
नाम | अंतिम | उच्च | निम्न | बदलाव | बदलाव % | वॉल्यूम | समय | ||
---|---|---|---|---|---|---|---|---|---|
49.85 | 51.00 | 49.00 | +1.250 | +2.57% | 287.63K | NSE | |||
479.85 | 494.70 | 476.75 | +2.50 | +0.52% | 156.63K | NSE | |||
0.00 | 0.00 | 0.00 | 0.00 | 0.00% | 0.00 | NSE | |||
223.00 | 225.80 | 220.80 | +2.90 | +1.32% | 6.40M | NSE | |||
2,700.00 | 2,720.00 | 2,652.15 | +49.50 | +1.87% | 686.90K | NSE | |||
332.80 | 334.85 | 328.00 | +6.15 | +1.88% | 3.20M | NSE | |||
24.59 | 24.59 | 24.59 | +1.17 | +5.00% | 9.72K | BSE | |||
1.10 | 1.10 | 1.06 | +0.05 | +4.76% | 576.71K | BSE | |||
83.75 | 86.80 | 82.85 | -1.45 | -1.70% | 897.15K | NSE | |||
143.20 | 144.50 | 138.15 | +6.70 | +4.91% | 1.51M | NSE | |||
80.30 | 82.30 | 73.05 | +7.90 | +10.91% | 892.85K | BSE | |||
34.80 | 34.80 | 34.50 | +1.65 | +4.98% | 441.32K | BSE | |||
68.10 | 69.45 | 63.90 | +1.95 | +2.95% | 164.68K | NSE | |||
7.50 | 7.60 | 7.40 | +0.150 | +2.04% | 27.63M | NSE | |||
234.40 | 234.40 | 217.25 | +21.30 | +10.00% | 3.71M | NSE |